Getting a Preliminary Injunction for Pharmaceutical Patent Infringement in Germany (2026): When It Works, What Evidence You Need & Cross‑border Enforcement

Pharmaceutical patent injunction germany strategy has become one of the most pressing questions for in‑house counsel and IP managers heading into 2026, as cross‑border enforcement, import‑blocking measures and expedited interim relief converge into a single tactical toolkit. German courts remain among the most patentee‑friendly forums in Europe for fast, effective interim relief, and when combined with EU customs border measures the practical reach of a German order can extend well beyond national borders. This guide explains when German courts grant preliminary injunctions in pharmaceutical patent disputes, the evidence you should assemble, how to operationalise customs seizures, and how to coordinate enforcement across the EU and beyond.

It is written for decision‑makers who need to move quickly and prepare a filing that survives judicial scrutiny.

Intro, why a pharmaceutical patent injunction germany matters in 2026

Interim relief is no longer a defensive afterthought. In 2026, cross‑border enforcement activity remains a significant concern, driven by imports entering the EU and the increasing coordination between civil courts and customs authorities. For a patentee facing an imminent generic or biosimilar launch, a preliminary injunction in Germany can halt manufacture, sale and distribution quickly, preserving market exclusivity while the main action is decided. The practical effect is that interim measures have shifted from a niche procedural device to a front‑line commercial measure.

Note that since the launch of the Unified Patent Court (UPC) in June 2023, patentees holding European patents (that have not been opted out) have an additional forum for provisional measures with potentially multi‑state effect; this guide focuses on the German national route, but the UPC should be considered as a parallel option.

Before committing resources, decision‑makers should keep three points front of mind:

• When to consider an injunction. Pursue interim relief where there is a clear, demonstrable infringement and genuine urgency, an imminent or ongoing launch, importation or distribution that will cause serious, difficult‑to‑remedy commercial harm.
• Top evidence items. Precise claim mapping, a signed expert technical declaration, regulatory documents (marketing authorisation and supplementary protection certificate status) and documentary proof of urgency are the backbone of any credible filing.
• The customs option. Regulation (EU) No 608/2013 allows customs to suspend the release of suspected infringing goods at the border, a rapid, parallel measure that complements civil proceedings.

When German courts grant preliminary injunctions (legal test & procedure)

The procedural framework for interim relief sits in the German Code of Civil Procedure (Zivilprozessordnung, ZPO), while the substantive rights being enforced derive from the German Patent Act (Patentgesetz, PatG). The ZPO governs the mechanics of the einstweilige Verfügung, the preliminary injunction, including the requirements of urgency, the taking of security, and the manner in which orders are enforced. The PatG defines the patent right, the scope of protection and the exclusive entitlements that an injunction is designed to preserve.

The core requirements for a pharmaceutical patent injunction germany application

German courts assess preliminary injunction applications against a well‑established set of thresholds. In broad terms, a successful applicant must demonstrate:

• A prima facie case of infringement (Verfügungsanspruch). The court must be satisfied, on the evidence put before it at an early stage, that the defendant’s product or process falls within the scope of the asserted claims. This is where claim mapping and expert declarations are decisive.
• Urgency (Verfügungsgrund). The applicant must show that the matter cannot await the outcome of ordinary proceedings. Delay in bringing the application, once the patentee knew or should have known of the infringement, can defeat urgency.
• A balance of interests and proportionality. The court weighs the harm to the patentee against the harm to the defendant, taking account of the public interest, which in pharmaceutical matters can include patient access and supply considerations.
• Sufficient certainty on validity. In patent matters, German courts have traditionally expected a reasonable degree of confidence that the patent is valid. Following the Court of Justice of the EU decision in Phoenix Contact (C‑44/21, 2022), German courts no longer require as a strict precondition that the patent have survived first‑instance opposition or nullity proceedings; nonetheless, the validity position remains a central factor in the overall assessment.

The patent’s status can be verified through the register maintained by the German Patent and Trade Mark Office (DPMA) for German national patents, or the European Patent Register maintained by the European Patent Office for European patents. Checking the relevant register before filing is a basic but essential step, because an unexpected validity challenge can undermine the whole application.

Ex parte relief versus an inter partes hearing

German courts can grant a preliminary injunction either after an oral hearing with both parties present, or, in urgent cases, on an ex parte basis without first hearing the defendant. Ex parte relief is powerful and fast, but it carries risk: the defendant may apply to have the order set aside, and the court will scrutinise both the strength of the infringement case and the genuineness of the urgency. In pharmaceutical disputes, a protective brief (Schutzschrift) filed in advance by a potential defendant, typically through the central electronic register of protective briefs (Zentrales Schutzschriftenregister), can influence whether the court is willing to act without a hearing, so applicants should anticipate that the other side may have prepared the ground.

Jurisdiction and the specialised patent chambers

Patent infringement actions, including applications for interim relief, are heard by the regional courts (Landgerichte) that operate specialised patent chambers. A limited number of these courts, notably Düsseldorf, Mannheim, Munich and Hamburg, handle the majority of German patent litigation, and their judges bring deep technical familiarity to the assessment. The Federal Patent Court (Bundespatentgericht, BPatG) deals with validity questions such as nullity actions, while the Federal Court of Justice (Bundesgerichtshof, BGH) sits at the apex and shapes the standards applied to patent practice through its jurisprudence. Understanding this division, infringement in the civil courts, validity in the BPatG, final appellate guidance from the BGH, is essential when planning a pharmaceutical patent injunction germany strategy.

Procedure and timeline: a short flowchart

The procedural path for interim relief can be summarised as a sequence of decisions and filings:

1. Confirm patent status and scope via the DPMA register or European Patent Register.
2. Assemble the filing package: claim charts, infringement evidence, expert declaration, proof of urgency and a draft order.
3. File the application at the competent regional court’s patent chamber.
4. The court decides whether to grant ex parte or to list an expedited hearing.
5. If granted, the order is served and enforced; the defendant may apply to vary or set aside, and may file an appeal.
6. A main action on the merits typically follows to secure a final, permanent remedy.

From filing to decision, expedited proceedings can move within days to a few weeks, depending on urgency and whether the court lists a hearing, one of the principal reasons the German forum is so attractive for time‑critical pharmaceutical disputes. Timelines vary by court and by the complexity of the technical issues.

Evidence you need, technical, regulatory & commercial packages

A common reason applications fail is thin or poorly organised evidence. A preliminary injunction is often granted on the papers and at speed, so the filing must be persuasive on its face. Below is a structured approach to the evidence bundle, prioritised for the early stages after a decision to proceed.

Evidence for likelihood of infringement (claim mapping)

The infringement case rests on a clear, element‑by‑element comparison between the asserted claims and the accused product or process. A professional claim chart should:

• Set out each claim feature in a separate row.
• Identify the corresponding feature in the accused product, with a precise reference to the supporting evidence (analytical report, product label, patent specification).
• Address equivalents where literal infringement is not clear‑cut.
• Avoid gaps, an unmapped claim element is an invitation for the defendant to argue non‑infringement.

For pharmaceutical matters, analytical and comparative testing of the accused product is frequently decisive: chromatographic data, dissolution profiles, polymorph characterisation or formulation analysis can establish the technical correspondence that the claim chart asserts. Keep a documented chain of custody for any samples obtained, because the provenance of test material will be scrutinised.

Evidence of urgency and irreparable harm

Urgency must be proved, not assumed. Courts look for contemporaneous documentation showing when the patentee first became aware of the infringing activity and that it acted promptly thereafter. Supporting material includes:

• Dated records of when the suspected infringement was discovered (correspondence, market intelligence, tender notices).
• Evidence of imminent or ongoing launch, distribution agreements, order confirmations, pricing listings or reimbursement applications.
• Commercial data demonstrating harm: price erosion, loss of market share, the difficulty of recovering a lost launch window, and the practical difficulty of quantifying all damage.
• Customs intelligence where imports are suspected, shipment data, CN tariff codes and consignee details.

The harm narrative is particularly important in pharmaceutical disputes, where a single generic entry can trigger reference‑price and reimbursement effects across a market.

Expert declarations and technical appendices

A signed expert technical declaration is often the centrepiece of a pharmaceutical patent injunction germany filing. German courts place significant weight on credible, well‑reasoned technical evidence in patent proceedings. A strong declaration should:

• Identify the expert’s qualifications and independence.
• Explain the technical field and the person skilled in the art.
• Walk through the infringement analysis in plain, reasoned terms, cross‑referring to the claim chart.
• Where validity is likely to be challenged, pre‑empt the most obvious attacks.
• Be signed, dated and supported by annexed technical appendices.

Regulatory and commercial dossier

Pharmaceutical cases demand a regulatory layer that ordinary patent disputes do not. Assemble documentation of the marketing authorisation status of both the patentee’s and the accused product, any supplementary protection certificate (SPC) extending the term of protection, and labelling or summary‑of‑product‑characteristics evidence that confirms the therapeutic use and formulation at issue. This regulatory dossier ties the technical infringement case to the real‑world commercial activity the injunction is designed to stop.

A practical sample table of contents for the evidence bundle might include: (1) the patent and register extract; (2) claim charts; (3) expert declaration and appendices; (4) analytical and comparative test reports with chain of custody; (5) regulatory dossier (MA, SPC, labelling); (6) commercial and urgency evidence; (7) customs intelligence; and (8) the draft order. Detailed drafting of each component should be addressed with local patent counsel.

Customs & border measures: stopping imported medicines at the EU/German border

Civil injunctions are not the only route to rapid relief. Regulation (EU) No 608/2013 establishes a harmonised mechanism under which customs authorities can suspend the release of goods suspected of infringing certain intellectual property rights, including patents and SPCs. For pharmaceutical patentees facing imports, this border measure can intercept infringing consignments before they reach the market, often faster, and at lower initial cost, than full civil proceedings. Note that the Regulation covers goods under customs supervision; goods in free circulation within the EU are generally outside its scope.

How the customs mechanism works in Germany

The German customs administration (Zoll), through its central IP unit, administers IPR border measures in accordance with the Regulation. The process begins with an application for action (AFA), in which the rights holder asks customs to detain goods suspected of infringing its rights. The application must enable customs officers, who are not patent experts, to recognise suspect goods, so it should include clear product identification, images, distinguishing features and, where possible, intelligence on routes, consignors and consignees. German customs guidance sets out the forms and practical steps required to lodge and maintain an AFA.

Once an application is in place, customs can suspend the release of matching goods and notify the rights holder, who then has a short window to confirm whether the goods infringe and to initiate proceedings to determine infringement. In appropriate cases, customs may also act on its own initiative where it encounters suspect goods before an application is on file, giving the rights holder the opportunity to lodge an application within the period set by the Regulation.

Customs measures versus civil injunctions

The two routes are complementary rather than alternative. A civil preliminary injunction binds the named defendant and can reach manufacture, sale, distribution and recall within Germany; a customs measure operates at the border and stops physical goods regardless of whether civil proceedings have started. The evidentiary thresholds differ too: customs requires enough information to identify and detain suspect goods, whereas a court requires a reasoned prima facie infringement case and proof of urgency. The strongest strategies often run both in parallel.

What to do after a seizure

A customs detention is the beginning, not the end. After notification, the rights holder should move quickly to preserve the detained goods as evidence, obtain samples for analysis where permitted, and launch or accelerate civil proceedings to secure a binding order. Coordination between the customs team and the litigation team is essential, a border detention that is not followed by prompt proceedings within the deadlines set by the Regulation may lapse, releasing the goods.

Duration, enforcement & cross‑border options (EU & beyond)

A preliminary injunction is, by its nature, provisional. It typically remains in force until the main action decides the merits or until the court orders otherwise, and the court may require the claimant to commence substantive proceedings within a defined timeframe on the defendant’s application. The order is enforced through German enforcement channels, penalties for non‑compliance (such as administrative fines or, in extreme cases, detention of the responsible officer) can be imposed, and the order may include ancillary measures such as cease‑and‑desist obligations and, where justified, recall or destruction of infringing stock within Germany.

Security, bonds and cost exposure

Because interim relief is granted before the merits are fully tried, the court may require the claimant to provide security to cover the defendant’s potential losses if the injunction is later found to have been wrongly granted. Applicants should budget for this contingent exposure alongside the direct costs of expedited litigation. The ZPO governs these requirements, and early engagement with counsel on likely security levels is advisable so that financial approvals do not delay a time‑critical filing.

Enforcing a German order across the EU and internationally

A German injunction directly binds the parties and is enforceable in Germany. Extending its practical reach requires additional steps. Within the EU, recognition and enforcement of judgments between Member States is governed by the Brussels I Recast Regulation (Regulation (EU) No 1215/2012), subject to the limitations that apply to provisional measures; coordinated customs action under Regulation (EU) No 608/2013 allows border measures to be deployed at the external frontier of the Union. Where a European patent is in play and has not been opted out, the Unified Patent Court offers provisional measures with effect across participating Member States, which can be a more direct route to multi‑state relief than seeking to extend a national order.

For activity outside the EU, there is no automatic extension of a German order: rights holders generally rely on recognition procedures where available, or, more commonly in fast‑moving pharmaceutical disputes, pursue parallel filings in the relevant jurisdiction.

This is where the cross‑border enforcement trend bites. Where imports originate in or transit through non‑EU jurisdictions, coordinated action, a German pharmaceutical patent injunction germany filing combined with parallel customs applications and close cooperation with local counsel, typically delivers better practical outcomes than a single national order.

Tactical timeline & filing checklist (sample 7‑day action plan)

Speed is often decisive. The following sample timeline illustrates how a well‑prepared team can move from a standing start to a filed application and customs submission within a week. Adjust to the facts, but treat the sequence as a discipline rather than a rigid rule.

1. Day 0, Trigger and internal approval. Confirm the suspected infringement, secure internal sign‑off and budget authority (including contingent security), and instruct local patent counsel.
2. Day 1, Evidence harvest. Verify patent and SPC status on the relevant register, gather product samples with documented chain of custody, and collect commercial and urgency evidence.
3. Day 2, Expert instruction. Brief the technical expert, commission analytical testing where required, and begin the claim chart.
4. Day 3, Draft the filing. Finalise claim charts, draft the expert declaration, assemble the regulatory dossier and prepare the draft order with precise relief wording.
5. Day 4, Customs application. Lodge or update the application for action with German customs, with full product identification and intelligence.
6. Day 5, File in court. Submit the application to the competent regional court’s patent chamber, with all annexes, and request ex parte relief or an expedited hearing as appropriate.
7. Days 6–7, Service and follow‑through. Arrange service on the defendant, prepare for any hearing, and coordinate customs and civil teams on next steps.

Sample relief requests should be drafted tightly and may include: an order to cease manufacture, offering, sale and distribution; a recall of infringing stock; an obligation to render accounts; and a direction supporting customs notification. Equally important is the decision point about when not to pursue, where validity is fragile, urgency has lapsed through delay, or the public‑interest balance in a supply‑critical medicine weighs against interim relief, the better course may be to proceed straight to the main action.

Comparison table, civil preliminary injunction vs customs seizure/border measures

The table below contrasts the two principal routes to rapid relief. In practice, an effective pharmaceutical patent injunction germany strategy often deploys both in a coordinated sequence.

Case studies, common pitfalls & practical tips from counsel

Illustrative examples show the difference preparation makes. In one typical successful matter, a patentee facing an imminent generic launch combined a meticulous element‑by‑element claim chart, a robust expert declaration and dated urgency evidence; the regional court granted ex parte relief, and a parallel customs application intercepted an inbound consignment within the same period. The coordination of civil and customs tracks magnified the practical effect of each.

In a contrasting matter, an application failed because the expert declaration was generic, the claim chart left two features unmapped, and the regulatory dossier did not clearly tie the accused product to the asserted therapeutic use. The defendant exploited every gap, and the court declined relief. The lesson is consistent: German courts reward precision and punish ambiguity.

Common pitfalls to avoid include:

• Weak or boilerplate expert statements that do not engage with the specific technology.
• Incomplete claim mapping that leaves elements unaddressed.
• Delay between discovery of the infringement and filing, which defeats urgency.
• Missing regulatory proof connecting the patent to the accused product’s authorised use.
• Treating customs and civil tracks in isolation rather than coordinating them.

On cost and timing, applicants should expect to fund expert work, analytical testing, expedited counsel and contingent security, while recognising that a well‑run expedited application can produce a decision within days to a few weeks, a return that, in the pharmaceutical context, can justify the investment.

Conclusion

A pharmaceutical patent injunction germany strategy, executed well, remains one of the most effective tools available to rights holders in 2026, fast, broad in its reach within Germany, and increasingly powerful when paired with EU customs border measures and coordinated cross‑border enforcement. Success turns on preparation: a precise claim chart, a credible expert declaration, a complete regulatory dossier and demonstrable urgency, assembled at speed and filed before the commercial damage becomes irreversible. The patentees who succeed are those who treat the civil and customs routes as a single, coordinated campaign rather than separate tactics, and who consider whether the Unified Patent Court offers a more direct route to multi‑state relief.

For time‑critical matters, early engagement with specialist counsel, to assess the strength of the infringement case, verify patent status and plan the filing and customs application in parallel, is the decisive first step.

For tailored support, explore the Pharmaceutical practice area, Germany or find a pharmaceutical patent lawyer in Germany through the Global Law Experts directory.

This article is general information and not legal advice. Pharmaceutical patent enforcement is fact‑specific; verify current law and procedure and obtain qualified counsel before acting.

Sources

1. German Patent Act (PatG), official text
2. German Code of Civil Procedure (ZPO), official text
3. Regulation (EU) No 608/2013 concerning customs enforcement of IPRs
4. Regulation (EU) No 1215/2012 (Brussels I Recast)
5. German Customs (Zoll), Intellectual Property Rights guidance
6. Federal Patent Court (Bundespatentgericht, BPatG)
7. Federal Court of Justice (Bundesgerichtshof, BGH)
8. German Patent and Trade Mark Office (DPMA)
9. Unified Patent Court (UPC)